ProShares Trust - ProShares UltraShort Nasdaq Biotechnology -2x Shares Accounts Payable

ProShares Trust - ProShares UltraShort Nasdaq Biotechnology -2x Shares (BIS) currently reports a accounts payable of $2.7M as of December 2025. That compares with $3.2M in the prior-year period — down 17.2% year over year. Use the charts on this page to explore ProShares Trust - ProShares UltraShort Nasdaq Biotechnology -2x Shares's accounts payable history and peer comparisons.

ProShares Trust - ProShares UltraShort Nasdaq Biotechnology -2x Shares's accounts payable decreased from $3.2M to $2.7M — a 17.2% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ProShares Trust - ProShares UltraShort Nasdaq Biotechnology -2x Shares reported $2.7M in accounts payable as of December 2025. That compares with $3.2M in the prior-year period — down 17.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $2.7M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ProShares Trust - ProShares UltraShort Nasdaq Biotechnology -2x Shares, and consider following BIS for alerts when major investors trade the stock.